How serious is a 18 × 16 × 7 mm dural‑based, contrast‑enhancing lesion in the right anterior cranial fossa causing mild mass effect on the inferior frontal lobe, without edema, with chronic microvascular ischemic changes and modest, unchanged ventricular enlargement?

Interpretation of Dural-Based Lesion in Right Anterior Cranial Fossa

This 18 × 16 × 7 mm dural-based enhancing lesion in the right anterior cranial fossa is most likely a small meningioma that warrants close observation rather than immediate intervention, given its small size (<30 mm), minimal mass effect, absence of edema, and lack of symptoms. 1

Lesion Characteristics and Most Likely Diagnosis

The imaging features strongly suggest a meningioma:

• Dural-based location with homogeneous enhancement is the hallmark of meningioma, the most common extra-axial intracranial neoplasm 1
• Absence of vasogenic edema is reassuring—meningiomas causing significant edema typically require more aggressive management, but this lesion shows no appreciable parenchymal edema 2
• Mild mass effect only without midline shift, hydrocephalus, or brainstem compression indicates the lesion is not currently causing dangerous intracranial pressure 3, 1

However, approximately 7% of dural-based lesions that appear to be meningiomas on imaging prove to be something else on pathology 4. Alternative diagnoses to consider include hemangiopericytoma, lymphoma, schwannoma, Rosai-Dorfman disease, or rarely melanocytoma 5, 4, 6, 7.

Growth Pattern Assessment

The documented growth from 16 × 13 × 6 mm to 18 × 16 × 7 mm represents modest interval enlargement that shifts management considerations:

• Asymptomatic meningiomas <30 mm should be observed according to National Comprehensive Cancer Network guidelines 1
• However, documented growth on serial imaging is one criterion that favors surgical consideration even for small lesions 1
• The growth rate appears slow and the lesion remains below the 30 mm threshold where size alone would mandate intervention 1

Recommended Management Algorithm

Immediate Next Steps

Obtain dedicated MRI with contrast using a standardized meningioma protocol if not already performed with optimal sequences 1:

• High-resolution 3D T1-weighted pre- and post-contrast sequences (most critical for characterization) 1
• Axial T2-weighted and FLAIR sequences to confirm CSF cleft and assess for any subtle edema 1
• Susceptibility-weighted imaging (SWI) to detect calcifications 1
• Diffusion-weighted imaging (DWI) to evaluate cellularity 1

Clinical Assessment

Evaluate specifically for symptoms that would mandate intervention 1:

• Seizures (common with convexity lesions, though this is anterior cranial fossa/frontal base) 1
• Cognitive changes, personality changes, or executive dysfunction (frontal lobe involvement) 1
• Anosmia (anterior cranial fossa location near olfactory structures) 1
• Visual changes or cranial nerve deficits 1

Treatment Decision Based on Symptoms and Growth

If the patient remains asymptomatic:

• Continue observation with MRI surveillance every 6-12 months per American College of Radiology recommendations for WHO grade 1 meningiomas 1
• The documented growth warrants closer monitoring at 6-month intervals rather than annual 1

If symptoms develop or growth accelerates:

• Surgical resection becomes the treatment of choice for accessible anterior cranial fossa lesions 1
• This location is generally surgically accessible with acceptable risk 3, 1
• Complete resection with removal of dural attachment is optimal when feasible 1

If surgery is contraindicated due to medical comorbidities:

• Radiation therapy or radiosurgery may be considered as alternatives 1
• However, radiosurgery is not recommended for asymptomatic lesions that are surgically accessible 1

Additional Imaging Findings: Context and Implications

Chronic Microvascular Ischemic Changes

The T2/FLAIR hyperintensities in cerebral white matter represent moderate chronic small vessel disease 2:

• This is a separate, chronic process unrelated to the meningioma 2
• These changes do not represent vasogenic edema from the tumor, which would be focal and adjacent to the lesion 2
• Vascular risk factor modification (hypertension, diabetes, hyperlipidemia control) is appropriate 2

Ventricular Enlargement

The disproportionate ventricular enlargement (bifrontal horn 47 mm, third ventricle 15 mm) without change from prior imaging suggests:

• Central-predominant parenchymal volume loss (atrophy) is most likely given stability 1
• Normal pressure hydrocephalus (NPH) cannot be excluded and should be considered if the clinical triad develops: gait disturbance, cognitive decline, and urinary incontinence 1
• The absence of progression is reassuring that acute obstructive hydrocephalus from the meningioma is not occurring 3

Critical Pitfalls to Avoid

Do not assume this is definitively a meningioma without tissue diagnosis if:

• The lesion shows atypical features on optimized MRI (marked T2 hyperintensity or hypointensity, absence of dural tail, dural displacement sign, bone erosion) 4
• Rapid growth occurs on follow-up imaging 4
• The patient has no prior cancer history but this could represent first presentation of systemic disease 3

Do not initiate corticosteroids unless symptomatic vasogenic edema develops—this lesion currently shows no edema and steroids are not indicated 2

Do not delay surgical evaluation if:

• New neurological symptoms develop 1
• Accelerated growth is documented 1
• The lesion approaches or exceeds 30 mm 1

Do not pursue radiosurgery for an asymptomatic, surgically accessible lesion as this is not guideline-concordant management 1

Prognosis and Long-Term Outlook

If this proves to be a WHO grade 1 meningioma (most likely scenario):

• Complete surgical resection is curative in most cases, though recurrence rates can reach 20% within 25 years, necessitating long-term follow-up 1
• Observation alone is safe for asymptomatic small lesions, with intervention reserved for growth or symptom development 1
• Mortality risk from the lesion itself is very low given its small size, location, and lack of aggressive features 3, 1

The chronic microvascular changes and possible NPH represent separate concerns that may impact long-term cognitive function and quality of life independent of the meningioma 1, 2.